Towards Better Treatments For Acral Melanoma Through Functional Genomics
Funder
National Health and Medical Research Council
Funding Amount
$1,456,823.00
Summary
Acral melanoma is an uncommon melanoma subtype with bad prognosis that has been poorly characterised at the molecular level. The project will conduct comprehensive analysis of acral melanoma at the DNA, RNA and protein levels. Through subsequent functional follow-up studies of key drivers of this cancer type we will identify novel drug targets to treat this disease.
Therapeutic Targeting Of The Colorectal Cancer Epigenome
Funder
National Health and Medical Research Council
Funding Amount
$537,045.00
Summary
Enhancer RNAs (eRNAs) are a new class of noncoding RNA molecules that have been linked to diverse functions that impinge on cancer, but their clinical relevance is unknown. Our work shows that distinct eRNAs are expressed in a subset of cancer and predict which cancer will respond to a cancer therapeutic agent called a BET inhibitor. Our proposal uses sophisticated preclinical models and cutting edge technology to investigate the functional role of enhancers and enhancer templated RNA in cancer.
PROBE-NET: The Progression Of Barrett's Esophagus To Cancer Network
Funder
National Health and Medical Research Council
Funding Amount
$2,465,844.00
Summary
This application brings together the seven major research teams in Australia with expertise in oesophageal neoplasia to form a multi-state, multi-disciplinary Centre for Research Excellence. All of the nodes have worked together collaboratively for the past 4 years, pooling their expertise in surgery, gastroenterology, endoscopy, epidemiology, biostatistics, basic science, health policy and translational research. Our vision is to develop evidence-based strategies for reducing the burden of oeso ....This application brings together the seven major research teams in Australia with expertise in oesophageal neoplasia to form a multi-state, multi-disciplinary Centre for Research Excellence. All of the nodes have worked together collaboratively for the past 4 years, pooling their expertise in surgery, gastroenterology, endoscopy, epidemiology, biostatistics, basic science, health policy and translational research. Our vision is to develop evidence-based strategies for reducing the burden of oesophageal neoplasia.Read moreRead less
Defining Ubiquitin Ligase Substrates: New Therapeutic Strategies In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,163.00
Summary
Current cancer therapies use drugs that target both tumor cells and rapidly growing normal cells – causing side effects and limiting effectiveness. Newer treatments aim to target molecules that are unique to tumor cells, leaving normal cells unharmed. This project will study a process that tags proteins for destruction by a cellular recycling system, which is often disrupted in cancer. This research will not only help us understand how cancer develops, but also identify new targets for therapy.
A Functional In Vivo ShRNA Screen For Regulators Of Breast Cancer Metastasis.
Funder
National Health and Medical Research Council
Funding Amount
$555,417.00
Summary
Breast cancer is generally incurable if detected after the tumour has spread to other organs. The genes driving the tumour cells to other sites have not been clearly resolved. This project aims to accelerate the discovery process by using a genome wide functional screen to identify genes that control the spread of breast cancer. If successful, this project could lead very quickly to identification of genes that might be good targets for new therapy against advanced breast cancer.
A Systems Biology Approach To Defining Therapeutic Targets In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,112.00
Summary
Breast cancer is a very complex disease affecting large numbers of women. Current treatment strategies are effective at controlling the disease for patients, however many continue to be burdened by their disease as their tumour either does not respond or develops resistance to the treatment. We will use mathematical approaches to analyse large and complex data sets generated from breast cancers to identify new therapeutic targets and improve patient outcomes.
Cyclin E1 As A Therapeutic Target In Women With High-grade Serous Cancer And Primary Treatment Failure
Funder
National Health and Medical Research Council
Funding Amount
$644,170.00
Summary
Ovarian cancer is the 5th most common cancer in women and the most lethal gynaecologic malignancy. We found tumours with extra copies of the CyclinE1 gene (CCNE1) are less likely to respond to standard treatment, and show reliance on its activity. Therefore, targeting CCNE1 may be a novel treatment strategy for these cancers. We will perform preclinical studies with therapeutic inhibitors towards the CCNE1 pathway and further explore the underlying biology of tumours with CCNE1 amplification.